Efficiency of the D-chiro-inositol for the polycystic ovary syndrome

Authors

  • Т. Л. Архипкина State Institution “Institute of Endocrine Pathology Problems named after V.Y. Danilevskyi of the NAMS of Ukraine”, Kharkiv, Ukraine
  • Л. П. Любимова State Institution “Institute of Endocrine Pathology Problems named after V.Y. Danilevskyi of the NAMS of Ukraine”, Kharkiv, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2019.45.57-62

Keywords:

polycystic ovary syndrome, hyperinsulinemia, insulin resistance, hyperandrogeny, inositol, Protalis

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine disorder that develops in 10–15% of reproductive aged women. Over the past two decades, the inositol effectiveness in normalizing the clinical and hormonal disorders associated with PCOS has been actively studied. Inositol and its stereoisomers are classified as insulin sensitizers and act as a second conductor for insulin transmission routes. Myo-inositol and D-chiro-inositol are two of the nine existing stereoisomers the most studied currently, which play an important role in the PCOS physiology and treatment.

The aim of the study was to study the Protalis effectiveness in patients with PCOS. 40 women with PCOS (mean age 24.4 ± 0.8 years) who were resistant to previous treatment with clomiphene citrate were examined. Protalis was administered for three months, after the end of the drug intake clomiphene citrate was used according to the standard regimen to restore fertility.

The levels of luteinizing hormone, follicle-stimulating hormone, sex hormone binding globulin, total testosterone, antiMullerian hormone, homocysteine, folic acid were determined, and free androgen index was calculated. Fasting insulin was tested in serum and 120 minutes after the glucose load, the HOMA-IR was calculated, and lipid metabolism parameters were studied.

Monotherapy with Protalis normalized the menstrual cycle in 52.5%, restore ovulation in 40%, contributed to the pregnancy in 7.5% patients with PCOS, in combination with clomiphene citrate in 27.5% women previously resistant to clomiphene. No changes in body mass index, waist circumference/hip circumference or hirsutism were found. A decrease in hyperandrogenism due to a testosterone decrease and an sex hormone binding globulin increase was found, the carbohydrate, lipid metabolism, and folate status improved.

Protalis monotherapy can be recommended for patients with PCOS as a preliminary preparation, potentiating the clomiphene citrate effects, on the background insulin resistance. It is advisable to consider the Protalis use in combination with drugs for standard treatment of PCOS.

Author Biography

Т. Л. Архипкина, State Institution “Institute of Endocrine Pathology Problems named after V.Y. Danilevskyi of the NAMS of Ukraine”, Kharkiv

PhD

References

  1. Podzolkova, N.M., Koloda, Y.A. “Modern ideas about polycystic ovary syndrome.” Farmateka 3 (2016): 8–15.
  2. Rybalka, A.N., Pamfamirov, Y.K., Zabolotnov, V.A., et al. “Insulin resistance and its correction in patients with polycystic ovary syndrome.” Woman's Health 4 (2009): 125–7.
  3. Marshall, J.C., Dunaif, A. “Аll women with PCOS should be treated for insulin resistance.” Fertil Steril 97.1 (2012): 18–23.
  4. Macut, D., Bjekić-Macut, J., Rahelić, D., et al. “Insulin and the polycystic ovary syndrome.” Research and Clinical Practice 130 (2017): 163–70.
  5. El Hayek, S., Bitar, L., Hamdar, L.H., et al. “Poly Сystic Ovarian Syndrome: An Updated Overview.” Front Physiol 7 (2016): 124. DOI: 10.3389/fphys.2016.00124
  6. Højlund, K. “Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.” Dan Med J 61.7 (2014). Article ID B4890.
  7. Toprak, S., Yönem, A., Cakir, B., et al. “Insulin resistance in nonobese patients with polycystic ovary syndrome.” Horm Res 55.2 (2001): 65–70.
  8. Xu, X.F., De Pergola, G., Bjorntorp, P. “Testosterone increases lipolysis and the number of b-adrenoceptors in male rat adipocytes.” Endocrinology 128.1 (1991): 379–82.
  9. Diamanti-Kandarakis, E., Economou, F., Palimeri, S., Christakou, C. “Metformin in polycystic ovary syndrome.” Ann NY Acad Sci 1205 (2010): 192–8.
  10. Tang, T., Glanville, J., Hayden, C.J. “Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.” Hum Reprod 21.1 (2006): 80–9.
  11. Tang, T., Lord, J.M., Norman, R.J. “Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.” Cochrane Database Syst Rev 16.5 (2012): CD003053.
  12. Nestler, J.E., Unfer, V. “Reflections on inositol(s) for PCOS therapy: steps toward success.” Gynecological Endocrinology 31.7 (2015): 501–5. DOI: 10.3109/09513590.2015.1054802
  13. Di Paolo, G., De Camilli, P. “Phosphoinositides in cell regulation and membrane dynamics.” Nature 443 (2006): 651–7.
  14. Sortino, M.A., Salomone, S., Carruba, M.O., Drago, F. “Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols.” Frontiers in Pharmacology 8 (2017): 341. DOI: 10.3389/fphar.2017.00341
  15. Unfer, V., Nestler, J.E., Kamenov, Z.A., et al. “Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials.” International Journal of Endocrinology (2016): 1849162. DOI: 10.1155/2016/1849162
  16. Whiting, L., Danaher, R.N., Ruggiero, K., et al. “D-chiro-Inositol Attenuates Epinephrine-stimulated Hepatic Glucose Output in the Isolated Perfused Liver Independently of Insulin.” Horm Metab Res 45.5 (2013): 394–7. DOI: 10.1055/s-0032-1330016
  17. Baillargeon, J.P., Diamanti-Kandarakis, E., et al. “Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome.” Diabetes Care 29.2 (2006): 300–5.
  18. Nestler, J.E., Jakubowicz, D.J., de Vargas, A.F., et al. “Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system.” The Journal of Clinical Endocrinology Metabolism 83.6 (1998): 2001–5. DOI: 10.1210/jc.83.6.2001
  19. Sacchi, S., Marinaro, F., Tondelli, D., et al. “Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol.” Reprod Biol Endocrinol 14.1 (2016): 52–60. DOI: 10.1186/s12958-016-0189-2
  20. Galazis, N., et al. “D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.” Gynecol Endocrinol 27.4 (2011): 256–62. DOI: 10.3109/09513590.2010.538099
  21. Cheang, K.I., Baillargeon, J.P., Essah, P.A., et al. “Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome.” Metabolism 57.10 (2008): 1390–7. DOI: 10.1016/j.metabol.2008.05.008
  22. Bevilacqua, A., Carlomagno, G., Gerli, S., et al. “Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in Obstetrics and Gynecology – assisted reproduction technology.” Gynecol Endocrinol 31.6 (2015): 441–6. DOI: 10.3109/09513590.
  23. Kuznetsova, I.V., Kononova, V.A. “Folic acid and its role in the female reproduction of citratomerase.” Gynecology 4 (2014): 17–23.
  24. Tapilskaya, N.I., Aydukov, S.N. “Folate deficiency elimination - the main strategy of correclomiphene citratome homocysteine-dependent endothelial dysfomlofena citratoma.” Gynecology 3 (2013): 70–4.
  25. Ozay, A.C., Emekci Ozay, O., Okyay, R.E., et al. “Different Effects of Myoinositol plus Folic Acid versus Combined Oral Treatment on Androgen Levels in PCOS Women.” International Journal of Endocrinology (2016). DOI: 10.1155/2016/3206872

Downloads

Published

2019-04-03

How to Cite

Архипкина, Т. Л., & Любимова, Л. П. (2019). Efficiency of the D-chiro-inositol for the polycystic ovary syndrome. REPRODUCTIVE ENDOCRINOLOGY, (45), 57–62. https://doi.org/10.18370/2309-4117.2019.45.57-62

Issue

No. 45 (2019)

Section

Gynecology

License

Copyright (c) 2019 Т. Л. Архипкина, Л. П. Любимова

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.